Recent Updates
Recently added Catalysts

MLN6907

Phase 1

Imaging of Solid Gastrointestinal Tumors | Small Molecules | Oncology |Takeda Pharmaceutical Company Limited|Trials Updated: Jan 5, 2017

MLN6907 target and mechanism

ModalitySmall Molecules

Also known as [68Ga]MLN6907

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment20

FDA Designations

No designations recorded

MLN6907 clinical trials

MLN6907 · 1 trial · 1 indication

Phase 1 1
NCT02056015A Phase I Study of MLN6907 in Patients With Metastatic ColorectalImaging of Solid Gastrointestinal Tumors
COMPLETED20 Analytics
PHASE1COMPLETED
A Phase I Study of MLN6907 in Patients With Metastatic Colorectal
Imaging of Solid Gastrointestinal TumorsUnlock trial analytics

Study Endpoints

Primary Endpoints

Adverse events (AEs), serious AEs (SAEs), assessments of clinical laboratory values, and vital sign measurements
Duration of study up to 26 months
Human organ and whole body absorbed dose values from organ kinetic quantification of [68Ga]MLN6907 uptake and clearance
Day 1

Secondary Endpoints

Expert visual rating of [68Ga]MLN6907 liver tumor uptake and quantitative measurement of tumor-to-background (normal liver, muscle, etc.) ratio for each liver tumor
Duration of study up to 26 months
Time-activity curves for each liver tumor region of interest (ROI) and kinetic curves of the ratio of each liver tumor to background (including for normal liver, muscle, and blood); determination of the time for the maximum ratio for each tumor lesion
Duration of study up to 26 months
Plasma [68Ga]MLN6907 and MLN6907 drug substance precursor PK parameters and quantification of GCC levels in liver metastases
Day 1
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeDIAGNOSTIC

Treatment Arms

ArmTypeDescription
[68Ga]MLN6907EXPERIMENTAL -

Interventions

NameTypeDescription
[68Ga]MLN6907DRUGIV Administration of \[68Ga\]MLN6907 on Day 1
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria Each patient must meet all of the following inclusion criteria to be enrolled in the study: * Male or female patients 18 years or older. * Must be diagnosed with colorectal cancer (CRC) with liver metastasis and eligible and scheduled for resection of liver metastases as part of...

Countries:United StatesMexico
Unlock Eligibility Criteria

Frequently asked questions about MLN6907

What is MLN6907?

MLN6907 is an investigational small molecule imaging agent developed by Takeda Pharmaceutical Company Limited. It is being studied for imaging of solid gastrointestinal tumors, including metastatic colorectal cancer. MLN6907 is also known as [68Ga]MLN6907. It has completed a Phase 1 clinical trial and is not approved for commercial use.

What is MLN6907 used for?

MLN6907 is used for imaging of solid gastrointestinal tumors. It is being developed as a diagnostic imaging agent to visualize these tumors in patients. The Phase 1 study enrolled patients with metastatic colorectal cancer, a type of solid gastrointestinal tumor, to evaluate the agent's imaging properties.

Who is developing MLN6907?

MLN6907 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the sponsor of the clinical program evaluating MLN6907 for imaging of solid gastrointestinal tumors.

What phase is MLN6907 in?

MLN6907 is in Phase 1 clinical development. It has completed one Phase 1 trial and is investigational, meaning it has not been approved by the FDA or any regulatory agency for commercial use. The completed trial enrolled 20 patients and was conducted in the United States and Mexico.

What clinical trials is MLN6907 in?

MLN6907 has been studied in one completed Phase 1 clinical trial, NCT02056015, titled A Phase I Study of MLN6907 in Patients With Metastatic Colorectal. The trial enrolled 20 patients with imaging of solid gastrointestinal tumors, was uncontrolled, and took place in the United States and Mexico.

Is MLN6907 the same as [68Ga]MLN6907?

Yes, MLN6907 is also known as [68Ga]MLN6907. The bracketed notation indicates the drug is labeled with gallium-68, a radioactive isotope used in positron emission tomography imaging. Both names refer to the same investigational imaging agent developed by Takeda for solid gastrointestinal tumors.